AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20979460 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study 18779665 — intervention group
Group type: EXPERIMENTAL
Intervention: Punctal plugs
Number of subjects: 19
Study 18779665 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 19
Study 16957130 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients on dopamine agonists
Number of subjects: 297
Study 16957130 — intervention group
Group type: COMPARATOR
Intervention: Patients not specified as on dopamine agonists
Number of subjects: 297
Study 12562338 — intervention group
Group type: EXPERIMENTAL
Intervention: Wax epilation followed by long-pulsed alexandrite laser treatment
Number of subjects: 13
Study 12562338 — intervention group
Group type: COMPARATOR
Intervention: Unwaxed control areas
Number of subjects: 13
Study 10604304 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 164
Study 9104855 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Carbohydrate (Hi-CHO; 83% of energy)
Number of subjects: 7
Study 9104855 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Fat (Hi-Fat; 68% of energy)
Number of subjects: 7
Study 7880221 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7880221 — intervention group
Group type: EXPERIMENTAL
Intervention: Active medications and surgery
Number of subjects: 0
Study 7880221 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo effects
Number of subjects: 0
Study 7880221 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo effects plus disease natural history and regression to the mean
Number of subjects: 0
Study 2743378 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole (MN) applied to dentinal lesions covered by alpha‐tricalcium phosphate (TCP) cement for 1 day, 1 month, 1 year, and/or 2 years in vivo
Number of subjects: 0
Study 2743378 — intervention group
Group type: COMPARATOR
Intervention: Placebo (TCP cement without MN)
Number of subjects: 0
Study 938705 — intervention group
Group type: EXPERIMENTAL
Intervention: High-information stimuli (12, 26, or 60 bits of information)
Number of subjects: 90
Study 938705 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-duration stimuli (4.5 sec)
Number of subjects: 90
Study 938705 — intervention group
Group type: COMPARATOR
Intervention: Low-information stimuli (12, 26, or 60 bits of information)
Number of subjects: 90
Study 31780332 — intervention group
Group type: EXPERIMENTAL
Intervention: Penile prosthesis implantation without dilatation of the corpora cavernosa (n=80)
Number of subjects: 120
Study 31780332 — intervention group
Group type: COMPARATOR
Intervention: Penile prosthesis implantation with dilatation of the corpora cavernosa
Number of subjects: 120
Study 31780332 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall satisfaction reported
Number of subjects: 120
Study 31780332 — intervention group
Group type: EXPERIMENTAL
Intervention: Complications reported
Number of subjects: 120
Study 31240587 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed Martial Arts (MMA) intervention
Number of subjects: 0
Study 31240587 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control (WLC) group
Number of subjects: 0
Study 28873062 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% Lidocaine irrigation
Number of subjects: 84
Study 28873062 — intervention group
Group type: COMPARATOR
Intervention: Saline irrigation
Number of subjects: 84
Study 26218726 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous 5-0 nylon sutures
Number of subjects: 105
Study 26218726 — intervention group
Group type: COMPARATOR
Intervention: Interrupted 5-0 nylon sutures
Number of subjects: 105
Study 23835715 — intervention group
Group type: EXPERIMENTAL
Intervention: Obinutuzumab (GA101) 1,600/800 mg
Number of subjects: 40
Study 23835715 — intervention group
Group type: EXPERIMENTAL
Intervention: Obinutuzumab (GA101) 400/400 mg
Number of subjects: 40
Study 23835715 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 40
Study 22308802 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparins
Number of subjects: 0
Study 22308802 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux
Number of subjects: 0
Study 22308802 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical thromboprophylaxis
Number of subjects: 0
Study 22308802 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 20190923 — intervention group
Group type: EXPERIMENTAL
Intervention: Blocking the initiation of practice on review steps
Number of subjects: 0
Study 20190923 — intervention group
Group type: EXPERIMENTAL
Intervention: Removing payment for practice initiated after prompts (extinction)
Number of subjects: 0
Study 20190923 — intervention group
Group type: COMPARATOR
Intervention: Persistently repeated the same step
Number of subjects: 0
Study 16958565 — intervention group
Group type: COMPARATOR
Intervention: Risperidone (0.25-4.5 mg/day, mean dose 1.62 ± 1.02 mg/day)
Number of subjects: 25
Study 16958565 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (2.5-20 mg/day, mean dose 8.18 ± 4.41 mg/day)
Number of subjects: 25
Study 16958565 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (Risperidone and Olanzapine)
Number of subjects: 25
Study 15041031 — intervention group
Group type: COMPARATOR
Intervention: Fatty acid treatment
Number of subjects: 0
Study 10930796 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Number of subjects: 294
Study 10930796 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel
Number of subjects: 294
Study 7627087 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient supplementation (vitamin A, riboflavin, zinc, selenium)
Number of subjects: 298
Study 7627087 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactose capsule)
Number of subjects: 298
Study 7627087 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient supplementation
Number of subjects: 298
Study 7627087 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 298
Study 1645825 — intervention group
Group type: COMPARATOR
Intervention: Mixed bacterial vaccine (MBV) in Series 1
Number of subjects: 86
Study 1645825 — intervention group
Group type: COMPARATOR
Intervention: Mixed bacterial vaccine (MBV) in Series 2
Number of subjects: 86
Study 1645825 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed bacterial vaccine (MBV)
Number of subjects: 86
Study 7014286 — intervention group
Group type: EXPERIMENTAL
Intervention: Selsun Blue
Number of subjects: 199
Study 7014286 — intervention group
Group type: EXPERIMENTAL
Intervention: Head & Shoulders
Number of subjects: 199
Study 7014286 — intervention group
Group type: EXPERIMENTAL
Intervention: Flex
Number of subjects: 199
Study 7014286 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegrin
Number of subjects: 199
Study 31796477 — intervention group
Group type: EXPERIMENTAL
Intervention: Coupled Plasma Filtration and Adsorption (CPFA)
Number of subjects: 49
Study 31796477 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 49
Study 28367037 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical sodium diclofenac 0.1%
Number of subjects: 100
Study 28367037 — intervention group
Group type: COMPARATOR
Intervention: Artificial tear drop (placebo)
Number of subjects: 100
Study 26114901 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized cognitive training
Number of subjects: 42
Study 26114901 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 42
Study 24099839 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron sucrose (200mg immediately after each chemotherapy infusion)
Number of subjects: 64
Study 24099839 — intervention group
Group type: COMPARATOR
Intervention: Oral ferrous fumarate (200mg three times a day)
Number of subjects: 64
Study 24099839 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron sucrose
Number of subjects: 64
Study 24099839 — intervention group
Group type: COMPARATOR
Intervention: Oral ferrous fumarate
Number of subjects: 64
Study 21341889 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) for PTSD and depressive symptoms
Number of subjects: 150
Study 21341889 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 150
Study 19382089 — intervention group
Group type: EXPERIMENTAL
Intervention: High-efficiency hemodialysis
Number of subjects: 0
Study 19382089 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flux hemodialysis
Number of subjects: 0
Study 19382089 — intervention group
Group type: COMPARATOR
Intervention: Low-flux hemodialysis
Number of subjects: 0
Study 17607425 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with RRMS
Number of subjects: 115
Study 17607425 — intervention group
Group type: COMPARATOR
Intervention: Health controls
Number of subjects: 115
Study 15448447 — intervention group
Group type: EXPERIMENTAL
Intervention: A-V Impulse system
Number of subjects: 64
Study 15448447 — intervention group
Group type: COMPARATOR
Intervention: Elevation and plaster (Control)
Number of subjects: 64
Study 11447072 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial tissue Doppler (TD) imaging
Number of subjects: 43
Study 11447072 — intervention group
Group type: COMPARATOR
Intervention: Control group (age- and sex-matched)
Number of subjects: 43
Study 9727727 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg plus Pindolol 7.5 mg
Number of subjects: 80
Study 9727727 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine 20 mg plus Placebo
Number of subjects: 80
Study 9836512 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin 0.25 mU x kg(‐1) x min(‐1)
Number of subjects: 24
Study 9836512 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin 0.5 mU x kg(‐1) x min(‐1)
Number of subjects: 24
Study 9836512 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin 1.0 mU x kg(‐1) x min(‐1)
Number of subjects: 24
Study 9836512 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin (all dosages)
Number of subjects: 24
Study 9836512 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 24
Study 2501714 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric chondroitin sulfate (90 mg of iron)
Number of subjects: 12
Study 2501714 — intervention group
Group type: COMPARATOR
Intervention: Ferritin iron (91 mg)
Number of subjects: 12
Study 2501714 — intervention group
Group type: COMPARATOR
Intervention: Comparison of ferric chondroitin sulfate vs ferritin iron
Number of subjects: 12
Study 1018189 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimedial recessions followed by bilateral rectus resections when needed
Number of subjects: 49
Study 1018189 — intervention group
Group type: COMPARATOR
Intervention: Recession/resections performed initially and followed by the same procedure on the fellow eye
Number of subjects: 49
Study 31370871 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue-depleted evening light
Number of subjects: 0
Study 31370871 — intervention group
Group type: COMPARATOR
Intervention: Normal lighting conditions
Number of subjects: 0
Study 27798388 — intervention group
Group type: EXPERIMENTAL
Intervention: Office-based recall (Group B)
Number of subjects: 87
Study 27798388 — intervention group
Group type: EXPERIMENTAL
Intervention: Outsourced recall (Group C)
Number of subjects: 87
Study 27798388 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Group A)
Number of subjects: 87
Study 26173554 — intervention group
Group type: COMPARATOR
Intervention: Mailed toolkit delivery (minimal intensity)
Number of subjects: 42
Study 26173554 — intervention group
Group type: COMPARATOR
Intervention: Mailed toolkit delivery with quarterly audit and feedback reports (moderate intensity)
Number of subjects: 42
Study 26173554 — intervention group
Group type: COMPARATOR
Intervention: In-person toolkit delivery with academic detailing, on-site behavioral management training, and quarterly audit and feedback reports (high intensity)
Number of subjects: 42
Study 26173554 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (comparison of prescribing levels)
Number of subjects: 42
Study 23941549 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.6 μg/kg/h continuous infusion)
Number of subjects: 20
Study 23941549 — intervention group
Group type: COMPARATOR
Intervention: Saline (0.9% sodium chloride for injection, maintenance infusion)
Number of subjects: 20
Study 21304097 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom onset-to-balloon time <3 hours
Number of subjects: 5745
Study 21304097 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom onset-to-balloon time 3 to 5 hours
Number of subjects: 5745
Study 21304097 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom onset-to-balloon time >5 hours
Number of subjects: 5745
Study 21304097 — intervention group
Group type: EXPERIMENTAL
Intervention: Door-to-balloon time <60 minutes
Number of subjects: 5745
Study 21304097 — intervention group
Group type: EXPERIMENTAL
Intervention: Door-to-balloon time 60 to 90 minutes
Number of subjects: 5745
Study 21304097 — intervention group
Group type: EXPERIMENTAL
Intervention: Door-to-balloon time 90 to 120 minutes
Number of subjects: 5745
Study 21304097 — intervention group
Group type: EXPERIMENTAL
Intervention: Door-to-balloon time ≥120 minutes
Number of subjects: 5745
Study 19396417 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term psychoanalysis (defined as fewer than 50 treatment sessions)
Number of subjects: 0
Study 19396417 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychodynamic short-term interventions
Number of subjects: 0
Study 19396417 — intervention group
Group type: COMPARATOR
Intervention: Cognitive interventions
Number of subjects: 0
Study 16708040 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral intervention (10-contact, 18-week duration)
Number of subjects: 237
Study 16708040 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral intervention
Number of subjects: 237
Study 16708040 — intervention group
Group type: COMPARATOR
Intervention: Conventional care (control group)
Number of subjects: 237
Study 15329210 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegasys (180 microg injection once a week for 24 weeks)
Number of subjects: 197
Study 15329210 — intervention group
Group type: COMPARATOR
Intervention: Roferon-A (3 MU injection three times a week for 24 weeks)
Number of subjects: 197
Study 15329210 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV genotype
Number of subjects: 197
Study 11532743 — intervention group
Group type: EXPERIMENTAL
Intervention: Piribedil
Number of subjects: 60
Study 11532743 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 9863112 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated traditional Chinese and Western medicine (TCM‐WM)
Number of subjects: 146
Study 9863112 — intervention group
Group type: COMPARATOR
Intervention: Western medicine alone
Number of subjects: 146
Study 8322986 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 57
Study 8322986 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 57
Study 3535552 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose piperacillin
Number of subjects: 0
Study 3535552 — intervention group
Group type: COMPARATOR
Intervention: Triple dose cefoxitin
Number of subjects: 0
Study 29955115 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone treatment in ASD patients
Number of subjects: 84
Study 27286179 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot condition (34.5°C)
Number of subjects: 10
Study 27286179 — intervention group
Group type: COMPARATOR
Intervention: Thermoneutral condition (20°C)
Number of subjects: 10
Study 25085771 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (positive control)
Number of subjects: 88
Study 25085771 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted selective treatment (TST)
Number of subjects: 88
Study 25085771 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (control and TST)
Number of subjects: 88
Study 22445779 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gum for 5 min (Time 1: T1)
Number of subjects: 14
Study 22445779 — intervention group
Group type: COMPARATOR
Intervention: Keeping the jaw relaxed for 5 min (Time 2: T2)
Number of subjects: 14
Study 19398787 — intervention group
Group type: EXPERIMENTAL
Intervention: Diluted povidone-iodine
Number of subjects: 60
Study 19398787 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 60
Study 19398787 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-pin fixation
Number of subjects: 60
Study 19398787 — intervention group
Group type: EXPERIMENTAL
Intervention: Wire fixation
Number of subjects: 60
Study 17533176 — intervention group
Group type: EXPERIMENTAL
Intervention: Lucinactant
Number of subjects: 1546
Study 17533176 — intervention group
Group type: COMPARATOR
Intervention: Colfosceril
Number of subjects: 1546
Study 17533176 — intervention group
Group type: COMPARATOR
Intervention: Beractant
Number of subjects: 1546
Study 17533176 — intervention group
Group type: COMPARATOR
Intervention: Poractant alfa
Number of subjects: 1546
Study 17533176 — intervention group
Group type: COMPARATOR
Intervention: Animal-derived surfactants (beractant and poractant)
Number of subjects: 1546
Study 15768833 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 104
Study 15768833 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 104
Study 11472451 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide, 1‐4 mg at mealtimes
Number of subjects: 256
Study 11472451 — intervention group
Group type: COMPARATOR
Intervention: Glipizide, 5‐15 mg daily
Number of subjects: 256
Study 11472451 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall results
Number of subjects: 256
Study 11472451 — intervention group
Group type: EXPERIMENTAL
Intervention: Minor hypoglycaemia
Number of subjects: 256
Study 9509197 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-stat acid-base management
Number of subjects: 20
Study 9509197 — intervention group
Group type: COMPARATOR
Intervention: pH-stat acid-base management
Number of subjects: 20
Study 7823337 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal sonography
Number of subjects: 51
Study 7823337 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysteroscopy
Number of subjects: 51
Study 7823337 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal sonography with endometrial thickness of 8 mm
Number of subjects: 51
Study 7823337 — intervention group
Group type: COMPARATOR
Intervention: Dilatation and curettage (gold standard)
Number of subjects: 51
Study 3292303 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose (n = 15)
Number of subjects: 28
Study 3292303 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 13)
Number of subjects: 28
Study 6451461 — intervention group
Group type: EXPERIMENTAL
Intervention: DS 103-282 (5 mg, three times daily for 7 days)
Number of subjects: 30
Study 6451461 — intervention group
Group type: COMPARATOR
Intervention: Diazepam (5 mg, three times daily for 7 days)
Number of subjects: 30
Study 31999308 — intervention group
Group type: EXPERIMENTAL
Intervention: SNORE Utility Index (developed from SF-6D utility index)
Number of subjects: 500
Study 31692553 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin orally for 6 days
Number of subjects: 96
Study 31692553 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antibiotic treatment)
Number of subjects: 96
Study 31692553 — intervention group
Group type: EXPERIMENTAL
Intervention: PPM positive group
Number of subjects: 96
Study 31692553 — intervention group
Group type: COMPARATOR
Intervention: PPM negative group
Number of subjects: 96
Study 27908227 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (10,000 IU soft gels administered three times per week)
Number of subjects: 152
Study 27908227 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vitamin A soft gels devoid of active ingredients administered thrice weekly)
Number of subjects: 152
Study 25015398 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver segmentation and MRI-based PDFF estimation
Number of subjects: 43
Study 25117183 — intervention group
Group type: EXPERIMENTAL
Intervention: Vandetanib + Metformin 1000 mg
Number of subjects: 79
Study 25117183 — intervention group
Group type: EXPERIMENTAL
Intervention: Vandetanib + Digoxin 0.25 mg
Number of subjects: 79
Study 25117183 — intervention group
Group type: EXPERIMENTAL
Intervention: Vandetanib + Midazolam 7.5 mg
Number of subjects: 79
Study 25117183 — intervention group
Group type: EXPERIMENTAL
Intervention: Vandetanib + Omeprazole 40 mg
Number of subjects: 79
Study 25117183 — intervention group
Group type: EXPERIMENTAL
Intervention: Vandetanib + Ranitidine 150 mg
Number of subjects: 79
Study 20842517 — intervention group
Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser
Number of subjects: 40
Study 20842517 — intervention group
Group type: COMPARATOR
Intervention: CVD bur
Number of subjects: 40
Study 20842517 — intervention group
Group type: COMPARATOR
Intervention: Diamond bur
Number of subjects: 40
Study 20842517 — intervention group
Group type: COMPARATOR
Intervention: Carbide bur
Number of subjects: 40
Study 19251685 — intervention group
Group type: EXPERIMENTAL
Intervention: Stratified program designed to correct initial movement errors
Number of subjects: 173
Study 19251685 — intervention group
Group type: COMPARATOR
Intervention: Generalized program with the same exercises for all
Number of subjects: 173
Study 19251685 — intervention group
Group type: EXPERIMENTAL
Intervention: High school subjects
Number of subjects: 173
Study 19251685 — intervention group
Group type: COMPARATOR
Intervention: Pre-high school subjects
Number of subjects: 173
Study 17479946 — intervention group
Group type: EXPERIMENTAL
Intervention: SQV-RTV-ATV regimen (1500 mg saquinavir, 100 mg ritonavir, 300 mg atazanavir once per day without NRTIs)
Number of subjects: 25
Study 17479946 — intervention group
Group type: EXPERIMENTAL
Intervention: SQV-RTV-ATV regimen
Number of subjects: 25
Study 17479946 — intervention group
Group type: COMPARATOR
Intervention: SQV formulations (200 mg vs. 500 mg)
Number of subjects: 25
Study 15841774 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin-to-skin contact immediately after birth
Number of subjects: 60
Study 15841774 — intervention group
Group type: COMPARATOR
Intervention: No skin-to-skin contact
Number of subjects: 60
Study 12365904 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser trabeculoplasty plus topical betaxolol hydrochloride (n = 129)
Number of subjects: 255